Company Profile
Galera Therapeutics Stock Price, News & Catalysts
- Ticker:
- GRTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
17.60 USD (-2.22%)
Close
Last updated: July 10, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for GRTX.
Company overview
Oncology Biotechnology Company in Transition
Galera Therapeutics entered 2026 focused on an acquired nitric-oxide-synthase inhibitor for difficult-to-treat breast cancers while pursuing a strategic combination with Obsidian Therapeutics. The planned combination shifts the principal operating focus toward engineered tumor-infiltrating lymphocyte therapies.
Tilarginine Pan-NOS Program
Tilarginine is a pan-inhibitor of nitric oxide synthase. The program is based on evidence that nitric oxide signaling can support tumor initiation, progression, metastasis, and immune suppression in certain cancers.
Metaplastic and Triple-Negative Breast Cancer
The lead Galera development focus is metaplastic breast cancer and other refractory subsets of triple-negative breast cancer, where nitric oxide synthase can be overexpressed and treatment options are limited.
Investigator-Sponsored Combination Study
An NIH-funded Phase 1/2 investigator-sponsored trial is evaluating tilarginine with nab-paclitaxel and alpelisib in metaplastic breast cancer. A separate triple-negative breast cancer study has also been contemplated through the I-SPY 2 consortium, subject to funding and development decisions.
Divested Dismutase-Mimetic Assets
Galera sold avasopasem, rucosopasem, and its other superoxide-dismutase-mimetic assets to Biossil. This transaction removed the company's former radiotherapy-support portfolio and left tilarginine as its principal legacy development asset.
Obsidian Combination and OBX-115
The strategic combination with Obsidian centers the combined company on OBX-115, an engineered autologous tumor-infiltrating lymphocyte therapy designed to produce regulated membrane-bound IL-15. OBX-115 is in clinical development for advanced melanoma and non-small cell lung cancer.
Future catalysts
- Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027.
- Registration-enabling OBX-115 data in advanced melanoma by year-end 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Galera Therapeutics (GRTX)?
Galera Therapeutics (GRTX) most recently closed at 17.60 USD, a -2.22% move versus the previous session.
What does Galera Therapeutics do?
Oncology Biotechnology Company in Transition Galera Therapeutics entered 2026 focused on an acquired nitric-oxide-synthase inhibitor for difficult-to-treat breast cancers while pursuing a strategic combination with Obsidian Therapeutics. The planned combination shifts the principal operating focus toward engineered tumor-infiltrating lymphocyte...
On which exchange is GRTX stock listed?
Galera Therapeutics (GRTX) is associated with NASDAQ, United States, Biopharma.
What is OBX-115?
Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027.
Which conditions is Galera Therapeutics targeting with OBX-115?
Galera Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Galera Therapeutics describe recent progress with OBX-115?
Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027.
What is IL-15?
Obsidian Combination and OBX-115 The strategic combination with Obsidian centers the combined company on OBX-115, an engineered autologous tumor-infiltrating lymphocyte therapy designed to produce regulated membrane-bound IL-15.
What should investors watch for with IL-15?
Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027. Registration-enabling OBX-115 data in advanced melanoma by year-end 2027.